,Technological approach,Antigen*
0,Recombinant subunit,EDIII-p64k fusion proteins and EDIII-capsid
1,vaccines,fusion proteins expressed in Escherichia coli
2,,Bivalent 80E-STF2 fusion proteins expressed
3,,in baculavirus/insect cells
4,,E protein
5,,80 E protein
6,,EDIII protein expressed in E. coli
7,prM/E expressed from plasmid vector,
8,VLP vaccines,prM/E
9,,EDIII-HBsAg VLPs or ectoE-based VLPs
10,,expressed in Pichia pastonis
11,,MVA-VLP
12,Recombinant chimeric,YF 17D backbone
13,live vaccines,
14,,DENV-2 backbone
15,,JE SA14-14-2 backbone
16,,Host range mutations
17,,Targeted mutation (2'-O-Methyltransferase
18,,mutant)
19,,DENV-4 backbone
20,,EDIII expressed from live-attenuated measles
21,,virus vector
22,Single round,EBS expressedfrom single-cycle VEE virus
23,replicating viruses,vector
24,,RepliVax
25,Virus-Vectored,Live adenovirus 4/7 oral vector
26,vaccines,
27,Purified inactivated,Purified inactivated
28,virus vaccines,
29,,Purified inactivated virus (+Venezuelan
30,,equine encephalitis - particle adjuvant)
